Authors: FISCHER AR ROSENBERG MA ROTH M LOPER M JUNGERWIRTH S ISRAEL E

Citation: Ar. Fischer et al., EFFECT OF A NOVEL 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR, BAYX-1005, ON ASTHMA INDUCED BY COLD DRY AIR, Thorax, 52(12), 1997, pp. 1074-1077

Authors: SCHACHTEL BP JUNGERWIRTH S WENGER WC WEISMAN SM

Citation: Bp. Schachtel et al., MYALGIA (MUSCULAR ACHINESS) - A NEW PLACEBO-CONTROLLED PAIN MODEL, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 14-14

Authors: GLASSER SP RIPA SR ALLENBY KS SCHWARTZ LA COMMINS BM JUNGERWIRTH S

Citation: Sp. Glasser et al., THE EFFICACY AND SAFETY OF ONCE-DAILY NIFEDIPINE ADMINISTERED WITHOUTFOOD - THE COAT-CORE FORMULATION COMPARED WITH THE GASTROINTESTINAL THERAPEUTIC SYSTEM FORMULATION IN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION, Clinical therapeutics, 17(2), 1995, pp. 296-312

Authors: MELTZER SS JOHNS MA RECHSTEINER EA JUNGERWIRTH S DAMICO JM BLEECKER ER

Citation: Ss. Meltzer et al., BRONCHODILATORY EFFECTS OF BAY1005, A 5-LIPOXYGENASE INHIBITOR, IN MILD-TO-MODERATE ASTHMA, Journal of allergy and clinical immunology, 93(1), 1994, pp. 294-294